Advertisement
Advertisement
U.S. markets close in 37 minutes
Advertisement
Advertisement
Advertisement
Advertisement

XORTX Therapeutics Inc. (XRTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.01000.0000 (0.00%)
As of 03:12PM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Momentum

Momentum

Previous Close1.0100
Open1.0300
Bid1.0100 x 900
Ask1.0300 x 1000
Day's Range1.0100 - 1.0596
52 Week Range0.8950 - 5.8900
Volume3,884
Avg. Volume511,893
Market Cap13.02M
Beta (5Y Monthly)0.46
PE Ratio (TTM)N/A
EPS (TTM)-0.2030
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for XRTX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • XORTX Therapeutics Inc.
    XRTX: Lowering target price to $3.00XORTX THERAPEUTICS INC has an Investment Rating of HOLD; a target price of $3.000000; an Industry Subrating of Medium; a Management Subrating of High; a Safety Subrating of Low; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    11 months agoArgus Research
View more
  • GlobeNewswire

    XORTX Announces US$5 Million Public Offering

    CALGARY, Alberta, Oct. 04, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, announces the pricing of an underwritten public offering of: (i) 1,400,000 common share units ("Common Share Units"), with each Common Share Unit consisting of one common share, no par value, and one warrant ("Warrant") to pur

  • GlobeNewswire

    XORTX Completes Positive Pre-Phase 3 Meeting with the US Food and Drug Administration

    CALGARY, Alberta, Sept. 19, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a clinical development stage pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce completion of the previously announced Type B Pre-phase 3 meeting with the US Food and Drug Administration (“FDA”) held on September 16, 2022. In advance of this meeting, XORTX submitted a “Pre-P

  • GlobeNewswire

    XORTX Sponsored Study Selected for Presentation at the American Society of Nephrology – Kidney Week 2022

    Hyperuricemia is Associated with Accelerated Polycystic Kidney Disease (“PKD”) InjuryCALGARY, Alberta, Sept. 01, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease is pleased to announce acceptance of a study abstract for presentation at the American Society of Nephrology (“ASN”) Kidney Week 2022 meeting

Advertisement
Advertisement